What actually improves health or function — and what does the benefit cost in risk, burden and uncertainty?
Interventions evaluates deliberate changes intended to improve healthspan or reduce age-related risk. The emphasis is on human outcomes, effect size, safety, feasibility and the population actually studied — not on how compelling the mechanism sounds.
Interventions: the main topic areas and reading framework.Published intervention evidence
Start with outcomes, not mechanisms
An intervention earns a stronger verdict when it improves outcomes that matter to people: disease events, physical or cognitive function, quality of life, disability or survival. Biomarker and pathway changes can support the story, but they do not substitute for meaningful human benefit.
Published intervention reviews
Only published articles assigned to Interventions appear here. Disease-specific, mechanistic or supplement content is not used as filler.
The same word — intervention — can describe exercise, an eating protocol, a prescription drug or an invasive procedure. These entry points keep those categories separate so benefit and risk are judged on an appropriate scale.
Exercise
The benchmark intervention: strong human evidence for function, cardiometabolic health and lower mortality risk, with benefits depending on dose, fitness and baseline health.
Caloric restriction
Human metabolic and risk-factor effects are real, but adherence, lean-mass preservation and the leap from improved markers to longer life need separate treatment.
Time-restricted eating
A practical eating-pattern intervention where timing, calorie intake, adherence and baseline metabolic health can explain very different study results.
Strong geroscience rationale and animal evidence meet an incomplete human longevity evidence base, making safety, dosing and endpoint interpretation central.
A well-established diabetes drug with observational longevity interest, but benefits in metabolically healthy adults remain a separate and unresolved question.
SGLT2 inhibitors
Prescription drugs with strong disease-specific cardiovascular and kidney outcomes; whether those benefits generalize into a longevity intervention is a different claim.
Sauna & passive heat
Promising physiological and observational evidence with lower intervention burden, but limited randomized evidence for hard longevity outcomes.
Therapeutic plasma exchange
An invasive and resource-intensive approach where early aging signals must be weighed against procedure burden, uncertainty and clinical indication.
Decision questions
Five questions before an intervention deserves a strong verdict
Mechanism is only the beginning. The decision changes when a benefit is meaningful, applies to the relevant population and is large enough to justify the harms and burden.
1 · What outcome improved?Separate a pathway signal or biomarker from physical function, disease events, disability, quality of life or survival.
2 · Who was actually studied?A benefit in people with diabetes, heart failure or frailty does not automatically apply to healthy adults seeking longevity.
3 · How large was the benefit?Relative changes can sound impressive while the absolute benefit is small. Magnitude, uncertainty and baseline risk all matter.
4 · What did it cost?Count adverse effects, monitoring, inconvenience, adherence burden, drug interactions, financial cost and opportunity cost.
5 · What remains uncertain?Ask whether the key gap is replication, longer follow-up, hard outcomes, healthy-population data, dose optimization or long-term safety.
Different interventions, different thresholds
Risk changes how much evidence is enough
A safe, reversible behavior and an off-label drug should not be judged with the same decision threshold. Higher risk, monitoring burden and irreversibility demand stronger evidence of meaningful human benefit.
Human trials exist, but outcomes and adherence vary by protocol and population.
Decision threshold
Benefits should justify burden and avoid avoidable nutritional or functional trade-offs.
Prescription drugs
Rapamycin, metformin, SGLT2 inhibitors
Evidence pattern
Drug-specific evidence may be strong for approved diseases yet weak for longevity in healthy adults.
Decision threshold
Off-label longevity use requires a much higher bar for benefit, safety and clinical oversight.
Procedures & emerging technologies
Plasma exchange and other invasive or experimental approaches
Evidence pattern
Often early-stage, heterogeneous or focused on biomarkers and feasibility.
Decision threshold
High burden and uncertainty demand stronger evidence before broad use can be justified.
Outcome ladder
What kind of result did the intervention actually produce?
A pathway change, a lower biomarker and a reduction in disability are all real findings, but they do not support the same claim. Intervention pages keep that distinction visible.
From target engagement to outcomes that matter
Outcome level
What it shows
Decision weight
Mechanism / target engagement
Shows that the intervention reached or changed the intended biological target.
Useful for plausibility; not evidence of health benefit.
Biomarker / risk factor
Shows a measurable physiological change associated with health or disease risk.
Potentially useful, but only as strong as the marker’s validation.
Function / symptoms / quality of life
Shows that people move, feel, think or function better in a meaningful way.
Directly relevant to healthspan when measured well.
Disease events / disability
Shows fewer clinically important events or delayed loss of independence.
Strong decision-relevant human outcome evidence.
Survival / healthy survival
Shows longer life or more time alive without major disease or disability.
Most directly aligned with longevity claims, but difficult and slow to establish.
From plausible to useful.Risk-adjusted evidence
Safety is part of the verdict, not a footnote
The same statistical benefit can lead to a different practical conclusion when adverse effects, monitoring, reversibility and opportunity cost differ.
Low-risk does not mean proven
Exercise and other low-risk behaviors can be sensible even when every longevity endpoint has not been tested, because broader health benefits and safety are already well established.
Approved for one disease ≠ proven for longevity
A prescription drug can have excellent evidence in heart failure or diabetes while remaining unproven for extending healthy life in otherwise healthy adults.
Monitoring burden counts as harm
Laboratory monitoring, clinician time, adherence complexity and interaction risk are part of the intervention cost, even when severe adverse events are uncommon.
Irreversibility raises the bar
The harder an intervention is to stop or undo — especially invasive procedures — the stronger the evidence should be before broad use is justified.
Intervention verdict
Five dimensions we keep separate
A useful verdict is not a single “works / does not work” label. It should show what the evidence says, how large the benefit is, what the intervention costs in risk and burden, and who the result actually applies to.
Human outcome evidenceHow directly has the intervention improved outcomes that matter to people?
Benefit magnitudeIs the effect large enough to matter at the individual or population level?
Safety burdenWhat adverse effects, contraindications, interactions or monitoring requirements come with it?
Practical burdenHow difficult, expensive or disruptive is sustained use in the real world?
GeneralisabilityDoes the evidence apply to healthy adults, or mainly to a specific disease or risk group?
Primary sources
Where intervention claims are checked
Intervention pages prioritize registered trials, primary human studies, systematic reviews and authoritative safety information. Mechanistic papers can explain why something might work; they do not substitute for outcome evidence.
Follow the intervention question into the right evidence layer
Interventions owns benefit-versus-burden decisions. Research owns new studies, Biology owns mechanism, Biomarkers owns measurement, and Supplements owns molecule-specific evidence when the intervention is a supplement.
Evidence standardsSee how outcome relevance, safety and uncertainty are weighted across intervention pages.
Start with outcomes, then price in the burden.
The strongest intervention is not the one with the most exciting mechanism. It is the one whose human benefit is meaningful enough to justify its risk, complexity and uncertainty.
